期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

噻唑烷二酮类药物改善非酒精性脂肪性肝病的作用机制 被引量：2

暂未订购
导出
摘要 非酒精性脂肪性肝病是一种由多病因引起的肝细胞内脂质蓄积过多的临床综合征, 其发病机制与胰岛素抵抗密切相关。噻唑烷二酮类胰岛素增敏剂,通过增加组织对胰岛素的敏感性,改善胰岛素抵抗、脂质代谢紊乱及调控脂肪细胞分泌等多方面的作用改善肝脏脂肪变性。
作者 王战建 张耀
机构地区 河北医科大学附属第三医院
出处 《世界临床药物》 CAS 2005年第12期739-742,共4页 World Clinical Drug
关键词 噻唑烷二酮类药物 非酒精性脂肪性肝病 胰岛素抵抗
分类号 R977.15 [医药卫生—药品]
  • 相关文献

参考文献10

  • 1Marchesini G,Brizi M,Bianchi G,et al.Nonalcoholic fatty liver disease: a feature of the metabolic syndrome[].Diabetes.2001
  • 2Matsuda J,Hosoda K,Itoh H,et al.Increased adipose expression of the uncoupling protein 3 gene by thiazolidinediones in Wistar fatty rats and in cultured adipocytes[].Diabetes.1998
  • 3Digby JE,Montague CT,Sewter CO,et al.Thiazolidinediones exposure increase the expression of uncouping protein 1 in cultured human pre-adipocytes[].Diabetes.1998
  • 4Neuschwander-Tetri BA,Brunt EM,Wehemeier KR,et al.Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone[].Hepatology.2003
  • 5Aimin Xu,Yu Wang,Hussila Keshaw,et al.The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice[].The Journal of Clinical Investigation.2003
  • 6Julia A,Balfour B,PIosker GL.Rosiglitazone[].Drugs.1999
  • 7Mayerson AB,Hundal RS,Dufour S,et al.The effects of rosiglitazone on insulin sensitivity,lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes[].Diabetes.2002
  • 8Marchesini G,Brizi M,Morselli-Labate AM,et al.Association of nonalcoholic fatty liver disease with insulin resisitance[].The American Journal of Medicine.1999
  • 9Williams LB,Fawcett RL,Waechter AS,et al.Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender[].The Journal of Clinical Endocrinology.2000
  • 10Kakuma T,Lee Y,Higa M,et al.Leptin,troglitazone, and the expressing of sterol regulatory element binding proteins in liver and pancreatic islets[].Proceedings of the National Academy of Sciences of the United States of America.2000

同被引文献11

  • 1金抒清,洪万东,黄智铭.噻唑烷二酮类对非酒精性脂肪性肝病的治疗作用及机制[J].医学综述,2007,13(10):766-768. 被引量：2
  • 2代雪枫,王洪飞.非酒精性脂肪肝病与肝癌[J].实用全科医学,2007,5(7):647-649. 被引量：14
  • 3Choudhury J,Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease[J]. Clin Liver Dis, 2004, 8 (3) :575-594.
  • 4Videla LA, Rodrigo R, Araya J, et al. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease [ J]. Trends Mol Med,2006,12 (12) :555-558.
  • 5Machado M, Cortez-pinto H. Non-alcoholic fatty liver disease and insulin resistance[ J]. Eur J Gastroenterol Hepatol,2005,17 ( 8 ) :823-826.
  • 6Belfort R, Harrison S A, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis[ J]. N Engl J Med,2006,355 (22) :2297-2307.
  • 7McCullough AJ. Update on nonalcoholic fatty liver disease [ J ]. J Clin Gastroentero1,2002,34 ( 3 ) : 255-262.
  • 8Kumar KS, Malet PF. Nonalcoholic steatohepatitis [ J ]. Mayo Clin Proc, 2000,75 (7) :733-739.
  • 9Day CP. Non-alcoholic steatohepatitis(NASH) :where are we now and where are we going[J]. Gut,2002,50(5) :585-585.
  • 10Sanyal AJ, Campbell-sargent C, Mirshahi F, et al. Nonalcoholic steato- hepatitis:association of insulin resistance and mitochandfia abnormali- ties [ J ]. Gastroenterology,2001,120 (5) : 1183-1197.

引证文献2

二级引证文献8

世界临床药物
2005年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部